This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anderson, W. F. Articles by Brinton, L. A. Search for Related Content PubMed PubMed Citation Articles by Anderson, W. F. Articles by Brinton, L. A. Social Bookmarking                            What's this?

Tumor Variants by Hormone Receptor Expression in White Patients With Node-Negative Breast Cancer From the Surveillance, Epidemiology, and End Results Database

From the Division of Cancer Prevention, Office of Special Population Research, and Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.

Address reprint requests to William F. Anderson, MD, MPH, National Cancer Institute Division of Cancer Prevention, Room EPN 211L, MSC-7322, 6130 Executive Blvd, Bethesda, MD 20892-7161; email wanderso@ mail.nih.gov.

PURPOSE: Hormone receptor expression (presence-positive or absence-negative) may reflect different stages of one disease or different breast cancer types. Determining whether hormone receptor expression represents one or more breast cancer phenotypes would have important paradigmatic and practical implications.

METHODS: Breast cancer records were obtained from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. The study included 19,541 non-Hispanic white women with node-negative breast cancer. Standard tumor cell characteristics and breast cancer-specific survival were analyzed by independent estrogen receptor (ER+ and ER-), independent progesterone receptor (PR+ and PR-), and joint ERPR expression (ER+PR+, ER+PR-, ER-PR+, and ER-PR-).

RESULTS: Age frequency density plots by hormone receptor expression showed two overlapping breast cancer populations with early-onset and/or late-onset etiologies. Independent ER+ and PR+ phenotype were associated with smaller tumor sizes, better grade, and better cancer-specific survival than ER- and PR- breast cancer types. Joint ERPR phenotype exhibited biologic gradients for tumor size, grade, and cancer-specific survival, which ranked from good to worse for ER+PR+ to ER+PR- to ER-PR+ to ER-PR-.

CONCLUSION: Variations of standard tumor cell characteristics and breast cancer–specific survival by hormone receptor expression in white patients with node-negative breast cancer suggested two breast cancer phenotypes with overlapping etiologies and distinct clinical features.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Q. Lew, N. D. Freedman, M. F. Leitzmann, L. A. Brinton, R. N. Hoover, A. R. Hollenbeck, A. Schatzkin, and Y. Park Alcohol and Risk of Breast Cancer by Histologic Type and Hormone Receptor Status in Postmenopausal Women: The NIH-AARP Diet and Health Study Am. J. Epidemiol., June 18, 2009; (2009) kwp120v1. [Abstract] [Full Text] [PDF]

				C.-H. Lin, J.-Y. Liau, Y.-S. Lu, C.-S. Huang, W.-C. Lee, K.-T. Kuo, Y.-C. Shen, S.-H. Kuo, C. Lan, J. M. Liu, et al. Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1807 - 1814. [Abstract] [Full Text] [PDF]

				A. A. Iverson, C. Gillett, P. Cane, C. D. Santini, T. M. Vess, L. Kam-Morgan, A. Wang, M. Eisenberg, C. M. Rowland, J. J. Hessling, et al. A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens J. Mol. Diagn., March 1, 2009; 11(2): 117 - 130. [Abstract] [Full Text] [PDF]

				B. Handy The Clinical Utility of Tumor Markers Lab Med, February 1, 2009; 40(2): 99 - 103. [Abstract] [Full Text] [PDF]

				J. L. Marti, A. Guth, A. Naik, and K. L. Hiotis Receptor Status and Ethnicity of Indigent Patients With Breast Cancer in New York City Arch Surg, December 1, 2008; 143(12): 1227 - 1230. [Abstract] [Full Text] [PDF]

				M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group J. Clin. Oncol., March 20, 2008; 26(9): 1419 - 1426. [Abstract] [Full Text] [PDF]

				A. Bardia, L. C. Hartmann, C. M. Vachon, R. A. Vierkant, A. H. Wang, J. E. Olson, T. A. Sellers, and J. R. Cerhan Recreational Physical Activity and Risk of Postmenopausal Breast Cancer Based on Hormone Receptor Status Arch Intern Med, December 11, 2006; 166(22): 2478 - 2483. [Abstract] [Full Text] [PDF]

				W. F. Anderson, R. M. Pfeiffer, G. M. Dores, and M. E. Sherman Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1899 - 1905. [Abstract] [Full Text] [PDF]

				K. W. Hance, W. F. Anderson, S. S. Devesa, H. A. Young, and P. H. Levine Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute J Natl Cancer Inst, July 6, 2005; 97(13): 966 - 975. [Abstract] [Full Text] [PDF]

				H J Huang, P Neven, M Drijkoningen, R Paridaens, H Wildiers, E Van Limbergen, P Berteloot, F Amant, I Vergote, and M R Christiaens Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer J. Clin. Pathol., June 1, 2005; 58(6): 611 - 616. [Abstract] [Full Text] [PDF]

				H. B. Nichols, A. Trentham-Dietz, R. R. Love, J. M. Hampton, P. T. Hoang Anh, D. C. Allred, S. K. Mohsin, and P. A. Newcomb Differences in Breast Cancer Risk Factors by Tumor Marker Subtypes among Premenopausal Vietnamese and Chinese Women Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 41 - 47. [Abstract] [Full Text] [PDF]

				T. A. King, M. L. Gemignani, W. Li, D. D. Giri, K. S. Panageas, F. Bogomolniy, C. Arroyo, N. Olvera, M. E. Robson, K. Offit, et al. Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers Cancer Res., August 1, 2004; 64(15): 5051 - 5053. [Abstract] [Full Text] [PDF]

				C. I. Li, K. E. Malone, and J. R. Daling Differences in Breast Cancer Hormone Receptor Status and Histology by Race and Ethnicity among Women 50 Years of Age and Older Cancer Epidemiol. Biomarkers Prev., July 1, 2002; 11(7): 601 - 607. [Abstract] [Full Text] [PDF]

				S. M. Swain Tamoxifen for Patients With Estrogen Receptor-Negative Breast Cancer J. Clin. Oncol., September 15, 2001; 19(90001): 93s - 97. [Full Text] [PDF]